医学
内科学
比例危险模型
肝硬化
危险系数
药方
对数秩检验
胃肠病学
丙型肝炎病毒
生存分析
中医药
传统医学
免疫学
病毒
替代医学
置信区间
药理学
病理
作者
Fuu Jen Tsai,Chi Fung Cheng,Chao‐Jung Chen,Chih Ying Lin,Yi Fang Wu,Te Mao Li,Po‐Heng Chuang,Yang Wu,Chih Ho Lai,Lei Xiang,Hsinyi Tsang,Ting Hsu Lin,Chien-Chang Liao,Shaohui Huang,Ju Pi Li,Ji-Ping Lin,Chih-Chien Lin,Wen Miin Liang,Ying Lin
出处
期刊:Phytomedicine
[Elsevier]
日期:2019-04-01
卷期号:57: 30-38
被引量:20
标识
DOI:10.1016/j.phymed.2018.09.237
摘要
Chinese herbal medicine (CHM) is a complementary natural medicine that is used widely for the treatment of hepatic diseases. The aim of this study was to investigate the effects of the long-term use of CHM for the treatment of liver diseases, as prescribed by TCM doctors, on overall mortality and hepatic outcomes in patients with HCV. We identified 98788 patients with HCV. Of these, 829 and 829 patients who were users and non-users of CHM, respectively, were matched for age, gender, CCI, and comorbidities prior to CHM treatment. The chi-squared test, Cox proportional hazard model, Kaplan–-Meier method, and log-rank test were used for comparisons. CHM users had a lower risk of overall mortality than non-users after adjustment for comorbidities by using a multivariate Cox proportional hazard model (p-value < 0.001; HR: 0.12, 95% CI: 0.06–0.26). In addition,the CHM users had a lower risk of liver cirrhosis than non-users after adjustment for comorbidities (p-value = 0.028; HR: 0.29, 95% CI: 0.09–0.88). The 12-year cumulative incidences of overall mortality and liver cirrhosis were lower in the CHM group (p-value < 0.05 for both, log rank test). The CHM co-prescription for Dan-Shen, Bie-Jia, Jia-Wei-Xiao-Yao-San => E-Shu was found to occur most often associated for the specific treatment of HCV infection. CHM as adjunctive therapy may reduce the overall mortality and the risk of liver cirrhosis in patients with HCV. The comprehensive list of the herbal medicines that may be used for the treatment of patients with HCV may be useful in future scientific investigations or for future therapeutic interventions to prevent negative hepatic outcomes in patients with HCV.
科研通智能强力驱动
Strongly Powered by AbleSci AI